The binding specificity of ZHER2:2395-IR700 was evaluated using a panel of breast and ovarian cancer cell lines expressing different HER2 levels as indicated by the Western blot (Fig. 1A). This evidence concerns the gene ERBB2 and ovarian carcinoma.